Englewood Cliffs, NJ – According to filings with the U.S. Securities and Exchange Commission, Aspargo Laboratories is raising $8,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Demurjian played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aspargo Laboratories

Aspargo Laboratories, Inc. has obtained an exclusive license for the U.S. commercialization rights of an oral suspension spray formulation of erectile dysfunction medication Sildenafil citrate, the active ingredient in Viagra, from Farmalider S.A. (Madrid), a leader in the Spanish OTC and ibuprofen market. Prescription oral suspension spray Sildenafil is supported by proven technology that is rapidly becoming available globally.

To learn more about Aspargo Laboratories, visit http://aspargolabs.com/

Contact:
Michael Demurjian, Chief Executive Officer
201-408-4831
https://www.linkedin.com/in/michael-demurjian-02868113/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved